The prevalence and risk factors of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

References

• Paulin F, Doyle TJ, Mercado JF, et al. Development of a risk indicator score for the identification of interstitial lung disease in patients with rheumatoid arthritis. Reumatol Clin. 2021;17(4):1–17. doi: 10.1016/j.reuma.2019.05.007.
   PubMed Web of Science ®Google Scholar
• Restrepo JF, Del Rincón I, Battafarano DF, et al. Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis. Clin Rheumatol. 2015;34(9):1529–1536. doi: 10.1007/s10067-015-3025-8.
   PubMed Web of Science ®Google Scholar
• Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168(2):159–166. doi: 10.1001/archinternmed.2007.59.
   PubMedGoogle Scholar
• Robles-Perez A, Luburich P, Rodriguez-Sanchon B, et al. Preclinical lung disease in early rheumatoid arthritis. Chron Respir Dis. 2016;13(1):75–81. doi: 10.1177/1479972315620746.
   PubMed Web of Science ®Google Scholar
• Zamora-Legoff JA, Krause ML, Crowson CS, et al. Patterns of interstitial lung disease and mortality in rheumatoid arthriti. Rheumatology. 2017;56(10):1825. doi: 10.1093/rheumatology/kex299.
   PubMedGoogle Scholar
• Richman NC, Yazdany J, Graf J, et al. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly hispanic and Asian patients. Medicine. 2013;92(2):92–97. doi: 10.1097/MD.0b013e318289ce01.
   PubMed Web of Science ®Google Scholar
• Carmona L, González-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis. 2003;62(9):897–900. doi: 10.1136/ard.62.9.897.
   PubMed Web of Science ®Google Scholar
• Norton S, Koduri G, Nikiphorou E, et al. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome. Rheumatology. 2013;52(1):99–110. doi: 10.1093/rheumatology/kes262.
   PubMed Web of Science ®Google Scholar
• Chen J, Shi Y, Wang X, et al. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clin Dev Immunol. 2013;2013:406927–406925. doi: 10.1155/2013/406927.
   PubMedGoogle Scholar
• Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583–1591. doi: 10.1002/art.27405.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li H, Wu N, et al. Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2017;36(4):817–823. doi: 10.1007/s10067-017-3561-5.
   PubMed Web of Science ®Google Scholar
• Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997;156(2 P 1):528–535. doi: 10.1164/ajrccm.156.2.9609016.
   PubMed Web of Science ®Google Scholar
• Bonilla Hernán MG, Gómez-Carrera L, Fernández-Velilla Peña M, et al. Prevalence and clinical characteristics of symptomatic diffuse interstitial lung disease in rheumatoid arthritis in a Spanish population. Rev Clin Esp. 2022;222(5):281–287. doi: 10.1016/j.rceng.2021.01.011.
   PubMedGoogle Scholar
• Fdda S, Khairy N, Fayed H, et al. Interstitial lung disease in Egyptian patients with rheumatoid arthritis: frequncy, pattern and correlation with clinical manifestations and anti-citrullinated peptide antibodies level. Egypt Rheumatol. 2018;40(3):155–160. doi: 10.1016/j.ejr.2017.10.006.
   Google Scholar
• Dhooria S, Babu V, Dhir V, et al. Factors associated with interstitial lung disease and the progressive fibrosing phenotype in rheumatoid arthritis–related interstitial lung disease. Medical J Armed Forces India. 2022. doi: 10.1016/j.mjafi.2022.08.004.
   Google Scholar
• Kakutani T, Hashimoto A, Tominaga A, et al. Related factors, increased mortality and causes of death in patients with rheumatoid arthritis-associated interstitial lung disease. Mod Rheumatol. 2020;30(3):458–464. doi: 10.1080/14397595.2019.1621462.
   PubMed Web of Science ®Google Scholar
• Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics–a large multicentre UK study. Rheumatology. 2014;53(9):1676–1682. doi: 10.1093/rheumatology/keu165.
   PubMed Web of Science ®Google Scholar
• Ong SG, Ding HJ, Zuhanis AH, et al. Predictors and radiological characteristics of rheumatoid arthritis-associated interstitial lung disease in a multi-ethnic Malaysian cohort. Med J Malaysia. 2022;77(3):292–299.
   PubMedGoogle Scholar
• Curtis JR, Sarsour K, Napalkov P, et al. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study. Arthritis Res Ther. 2015;17(1):319. doi: 10.1186/s13075-015-0835-7.
   PubMedGoogle Scholar
• Sparks JA, He X, Huang J, et al. Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis–associated interstitial lung disease: a prospective cohort study. Arthritis Rheumatol. 2019;71(9):1472–1482. doi: 10.1002/art.40904.
   PubMed Web of Science ®Google Scholar
• Page MJ, Mckenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Wells G, Shea B, O’connell J. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Health Research Institute Web site, 2014, 7.
   Google Scholar
• Zeng X, Zhang Y, Kwong JS, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8(1):2–10. doi: 10.1111/jebm.12141.
   PubMedGoogle Scholar
• Viera AJ. Odds ratios and risk ratios: what’s the difference and why does it matter?. South Med J. 2008;101(7):730–734. doi: 10.1097/SMJ.0b013e31817a7ee4.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. doi: 10.1002/sim.1186.
   PubMed Web of Science ®Google Scholar
• Borenstein M, Hedges LV, Higgins JP, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111. doi: 10.1002/jrsm.12.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi: 10.1136/bmj.315.7109.629.
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–463. doi: 10.1111/j.0006-341x.2000.00455.x.
   PubMed Web of Science ®Google Scholar
• Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyse. Medicine. 2019;98(23):e15987. doi: 10.1097/MD.0000000000015987.
   PubMed Web of Science ®Google Scholar
• Akiyama M, Kaneko Y, Yamaoka K, et al. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study.Rheumatol Int. 2016;36(6):881–889. J doi: 10.1007/s00296-016-3478-3.
   PubMed Web of Science ®Google Scholar
• Ben Tekaya A, Mokaddem S, Athimini S, et al. Risk factors for rheumatoid arthritis-associated interstitial lung disease: a retrospective study. Multidiscip Respir Med. 2022;17:877. doi: 10.4081/mrm.2022.877.
   PubMed Web of Science ®Google Scholar
• Chen HH, Chao WC, Chen YH, et al. Air pollutants and development of interstitial lung disease in patients with autoimmune diseases. Ann Rheum Dis. 2020;79(SUPPL 1):865.1–865. doi: 10.1136/annrheumdis-2020-eular.204.
   Google Scholar
• Ibfelt EH, Jacobsen RK, Kopp TI, et al. Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study. Rheumatology. 2021;60(1):346–352. doi: 10.1093/rheumatology/keaa327.
   PubMed Web of Science ®Google Scholar
• Juge PA, Lee JS, Lau J, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis. 2020;79(SUPPL 1):25.1–25. doi: 10.1136/annrheumdis-2020-eular.1678.
   Google Scholar
• Kiely P, Busby AD, Nikiphorou E, et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open. 2019;9(5):e028466. doi: 10.1136/bmjopen-2018-028466.
   PubMed Web of Science ®Google Scholar
• Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology. 2010;49(8):1483–1489. doi: 10.1093/rheumatology/keq035.
   PubMed Web of Science ®Google Scholar
• Kronzer VL, Huang W, Dellaripa PF, et al. Lifestyle and clinical risk factors for incident rheumatoid arthritis-associated interstitial lung disease. J Rheumatol. 2021;48(5):656–663. doi: 10.3899/jrheum.200863.
   PubMed Web of Science ®Google Scholar
• Li L, Liu R, Zhang Y, et al. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2020;39(5):1457–1470. doi: 10.1007/s10067-019-04846-1.
   PubMed Web of Science ®Google Scholar
• Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med. 2012;106(11):1591–1599. doi: 10.1016/j.rmed.2012.07.006.
   PubMed Web of Science ®Google Scholar
• Natalini JG, Baker JF, Singh N, et al. Autoantibody seropositivity and risk for interstitial lung disease in a prospective male-predominant rheumatoid arthritis cohort of US veterans. Ann Am Thorac Soc. 2021;18(4):598–605. doi: 10.1513/AnnalsATS.202006-590OC.
   PubMed Web of Science ®Google Scholar
• Rocha-Muñoz AD, Ponce-Guarneros M, Gamez-Nava JI, et al. Anti-Cyclic citrullinated peptide antibodies and severity of interstitial lung disease in women with rheumatoid arthritis. J Immunol Res. 2015;2015:151626–151610. doi: 10.1155/2015/151626.
   PubMed Web of Science ®Google Scholar
• Salaffi F, Carotti M, Di Carlo M, et al. High-resolution computed tomography of the lung in patients with rheumatoid arthritis: prevalence of interstitial lung disease involvement and determinants of abnormalities. Medicine. 2019;98(38):e17088. doi: 10.1097/MD.0000000000017088.
   PubMed Web of Science ®Google Scholar
• Samhouri BF, Vassallo R, Achenbach SJ, et al. Incidence, risk factors, and mortality of clinical and subclinical rheumatoid arthritis–associated interstitial lung disease: a population-based cohort. Arthritis Care Res. 2022;74(12):2042–2049. doi: 10.1002/acr.24856.
   Web of Science ®Google Scholar
• Severo CR, Chomiski C, Do Valle MB, et al. Assessment of risk factors in patients with rheumatoid arthritis-associated interstitial lung disease. J Bras Pneumol. 2022;48(6):e20220145. doi: 10.36416/1806-3756/e20220145.
   PubMed Web of Science ®Google Scholar
• Shidara K, Hoshi D, Inoue E, et al. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod Rheumatol. 2010;20(3):280–286. doi: 10.3109/s10165-010-0280-z.
   PubMed Web of Science ®Google Scholar
• Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum. 2006;54(5):1435–1439. doi: 10.1002/art.21806.
   PubMedGoogle Scholar
• Wang JX, Du CG. A retrospective study of clinical characteristics of interstitial lung disease associated with rheumatoid arthritis in Chinese patients. Med Sci Monit. 2015;21:708–715. doi: 10.12659/MSM.890880.
   PubMed Web of Science ®Google Scholar
• Wang T, Zheng XJ, Ji YL, et al. Tumour markers in rheumatoid arthritis-associated interstitial lung disease. Clin Exp Rheumatol. 2016;34(4):587–591.
   PubMed Web of Science ®Google Scholar
• Yin Y, Liang D, Zhao L, et al. Anti-cyclic citrullinated peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLOS One. 2014;9(4):e92449. doi: 10.1371/journal.pone.0092449.
   PubMed Web of Science ®Google Scholar
• Zhao N, Al-Aly Z, Zheng B, et al. Fine particulate matter components and interstitial lung disease in rheumatoid arthritis. Eur Respir J. 2022;60(1):2102149. doi: 10.1183/13993003.02149-2021.
   PubMed Web of Science ®Google Scholar
• Zheng B, De Moura CS, Machado M, et al. Association between chronic obstructive pulmonary disease, smoking, and interstitial lung disease onset in rheumatoid arthritis. Clin Exp Rheumatol. 2022;40(7):1280–1284. doi: 10.55563/clinexprheumatol/i9au1r.
   PubMed Web of Science ®Google Scholar
• Zheng M, Lou A, Zhang H, et al. Serum KL-6, CA19-9, CA125 and CEA are diagnostic biomarkers for rheumatoid arthritis-associated interstitial lung disease in the Chinese population. Rheumatol Ther. 2021;8(1):517–527. doi: 10.1007/s40744-021-00288-x.
   PubMed Web of Science ®Google Scholar
• Mitha M, Ghammo H, Connolly C, et al. Rheumatoid arthritis associated interstitial lung disease in KwaZulu-Natal, South Africa: clinical profile and treatment outcomes. European Respiratory Journal. 2020; 56 (suppl 64): 804. doi: 10.1183/13993003.congress-2020.804.
   Google Scholar
• Adegunsoye A, Oldham JM, Bellam SK, et al. African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis. Eur Respir J. 2018;51(6):1800255. doi: 10.1183/13993003.00255-2018.
   PubMed Web of Science ®Google Scholar
• Biederer J, Schnabel A, Muhle C, et al. Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol. 2004;14(2):272–280. doi: 10.1007/s00330-003-2026-1.
   PubMed Web of Science ®Google Scholar
• Suda T. Up-to-date information on rheumatoid arthritis-associated interstitial lung disease. Clin Med Insights Circ Respir Pulm Med. 2015;9(Suppl 1):155–162. doi: 10.4137/CCRPM.S23289.
   PubMedGoogle Scholar
• Gianfrancesco MA, Crowson CS. Where there’s smoke, there’s a joint: passive smoking and rheumatoid arthritis. Arthritis Rheumatol. 2021;73(12):2161–2162. doi: 10.1002/art.41940.
   PubMed Web of Science ®Google Scholar
• Albano SA, Santana-Sahagun E, Weisman MH. Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum. 2001;31(3):146–159. doi: 10.1053/sarh.2001.27719.
   PubMed Web of Science ®Google Scholar
• Sunyer J. Urban air pollution and chronic obstructive pulmonary disease: a review. Eur Respir J. 2001;17(5):1024–1033. doi: 10.1183/09031936.01.17510240.
   PubMed Web of Science ®Google Scholar
• Farhat SC, Silva CA, Orione MA, et al. Air pollution in autoimmune rheumatic diseases: a review. Autoimmun Rev. 2011;11(1):14–21. doi: 10.1016/j.autrev.2011.06.008.
   PubMed Web of Science ®Google Scholar
• Inui N, Enomoto N, Suda T, et al. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem. 2008;41(13):1074–1077. doi: 10.1016/j.clinbiochem.2008.06.014.
   PubMed Web of Science ®Google Scholar
• Conway R, Low C, Coughlan RJ, et al. Leflunomide use and risk of lung disease in rheumatoid arthritis: a systematic literature review and metaanalysis of randomized controlled trials. J Rheumatol. 2016;43(5):855–860. doi: 10.3899/jrheum.150674.
   PubMed Web of Science ®Google Scholar
• Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43(5):613–626. doi: 10.1016/j.semarthrit.2013.09.005.
   PubMed Web of Science ®Google Scholar
• Juge PA, Lee JS, Lau J, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021;57(2):2000337. doi: 10.1183/13993003.00337-2020.
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939. doi: 10.1002/acr.24596.
   PubMed Web of Science ®Google Scholar
• Alessandri C, Bombardieri M, Papa N, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis. 2004;63(10):1218–1221. doi: 10.1136/ard.2003.014647.
   PubMed Web of Science ®Google Scholar
• Kamiya H, Panlaqui OM. Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody. BMJ Open. 2021;11(3):e040465. doi: 10.1136/bmjopen-2020-040465.
   PubMed Web of Science ®Google Scholar
• Xie S, Li S, Chen B, et al. Serum anti-citrullinated protein antibodies and rheumatoid factor increase the risk of rheumatoid arthritis-related interstitial lung disease: a meta-analysis. Clin Rheumatol. 2021;40(11):4533–4543. doi: 10.1007/s10067-021-05808-2.
   PubMed Web of Science ®Google Scholar